154 related articles for article (PubMed ID: 34561883)
1. Hydroa vacciniforme-like lymphoproliferative disorder with eye involvement.
Feng X; Li F; Zhang Y; Wang L
Pediatr Dermatol; 2021 Sep; 38(5):1387-1388. PubMed ID: 34561883
[TBL] [Abstract][Full Text] [Related]
2. Ocular Involvement Preceded the Onset of Cutaneous Lesions in Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Case Report.
Zeng R; Du L; Wang D
Ocul Immunol Inflamm; 2022 Feb; 30(2):320-323. PubMed ID: 33021425
[TBL] [Abstract][Full Text] [Related]
3. Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients.
Xie Y; Wang T; Wang L
J Dermatol Sci; 2020 Aug; 99(2):128-134. PubMed ID: 32682634
[TBL] [Abstract][Full Text] [Related]
4. Hydroa Vacciniforme and Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Spectrum of Disease Phenotypes Associated with Ultraviolet Irradiation and Chronic Epstein-Barr Virus Infection.
Chen CC; Chang KC; Medeiros LJ; Lee JY
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297336
[TBL] [Abstract][Full Text] [Related]
5. Hydroa vacciniforme-like lymphoproliferative disorder: A retrospective study on clinicopathological characteristics of 32 cases.
Xu W; Tan J; Cai C; Lei L; Cao X; Zhou H; Xu M
Pediatr Dermatol; 2022 May; 39(3):372-375. PubMed ID: 35194837
[TBL] [Abstract][Full Text] [Related]
6. Oral manifestations of Hydroa vacciniforme-like lymphoproliferative disorder: a clinicopathological study of a Peruvian population.
López de Cáceres CVB; Rodrigues-Fernandes CI; Rendón Henao J; Morais TML; Soares CD; de Almeida OP; Fonseca FP; Delgado-Azañero W
J Oral Pathol Med; 2021 Jul; 50(6):530-539. PubMed ID: 34097774
[TBL] [Abstract][Full Text] [Related]
7. Hydroa vacciniforme-like lymphoproliferative disorder in Korea.
Han B; Hur K; Ohn J; Kim TM; Jeon YK; Kim YC; Mun JH
Sci Rep; 2020 Nov; 10(1):19294. PubMed ID: 33168864
[TBL] [Abstract][Full Text] [Related]
8. Hydroa vacciniforme-like lymphoproliferative disorder in an elderly Chinese patient and a literature review of adult cases.
Long V; Liang MW; Tan SH
Int J Dermatol; 2018 Nov; 57(11):1283-1292. PubMed ID: 29926891
[TBL] [Abstract][Full Text] [Related]
9. Clinicoprognostic Study of Hydroa Vacciniforme-like Lymphoproliferative Diseases: A Systematic Review.
Kim YJ; Yang HJ; Won CH; Chang SE; Lee MW; Lee WJ
Dermatology; 2023; 239(5):700-711. PubMed ID: 37231869
[TBL] [Abstract][Full Text] [Related]
10. Hydroa vacciniforme-like lymphoproliferative disorder in Ecuadorian children: A case series.
Garzón E; Dávila-Rodríguez JJ
Indian J Dermatol Venereol Leprol; 2023; 89(3):403-407. PubMed ID: 33871198
[TBL] [Abstract][Full Text] [Related]
11. Hydroa vacciniforme with ocular involvement.
Wisuthsarewong W; Leenutaphong V; Viravan S
J Med Assoc Thai; 1998 Oct; 81(10):807-11. PubMed ID: 9803075
[TBL] [Abstract][Full Text] [Related]
12. Hydroa Vacciniforme-like Lymphoproliferative disorder in an adult invades the liver and bone marrow with clear pathological evidence: a case report and literature review.
Wang X; Wang P; Wang A; Xu Y; Wang L; Chen Z
BMC Infect Dis; 2021 Jan; 21(1):17. PubMed ID: 33407199
[TBL] [Abstract][Full Text] [Related]
13. Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites.
Cohen JI; Manoli I; Dowdell K; Krogmann TA; Tamura D; Radecki P; Bu W; Turk SP; Liepshutz K; Hornung RL; Fassihi H; Sarkany RP; Bonnycastle LL; Chines PS; Swift AJ; Myers TG; Levoska MA; DiGiovanna JJ; Collins FS; Kraemer KH; Pittaluga S; Jaffe ES
Blood; 2019 Jun; 133(26):2753-2764. PubMed ID: 31064750
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases.
Guo N; Chen Y; Wang Y; Huang Y; Feng Y; Li M; Rao H
Diagn Pathol; 2019 Jul; 14(1):82. PubMed ID: 31315684
[TBL] [Abstract][Full Text] [Related]
15. Hydroa vacciniforme-like lymphoproliferative disorder: a retrospective cohort study of seven pediatric cases.
Ren F; Zhu J; Perry DM; Pruitt L; Elston DM
Int J Dermatol; 2020 Aug; 59(8):e290-e292. PubMed ID: 32403170
[No Abstract] [Full Text] [Related]
16. Hydroa vacciniforme-like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China.
Wang X; Liang Y; Yang Y; Li W; Wang G; Wang S; Li Y; Zhang M
J Dermatol; 2021 Sep; 48(9):1315-1326. PubMed ID: 33982815
[TBL] [Abstract][Full Text] [Related]
17. Artificial reproduction of atypical hydRoa vacciniforme caused by latent EpStein-Barr virus infection.
Heo EP; Park SH; Kim TH
Int J Dermatol; 2003 Jun; 42(6):476-9. PubMed ID: 12854510
[TBL] [Abstract][Full Text] [Related]
18. Hydroa Vacciniforme-like Lymphoproliferative Disorder Treated with Intravenous Immunoglobulin: Long-term Remission Without Haematopoietic Stem Cell Transplantation or Chemotherapy.
Ruan Y; Shen X; Shi R; Zhao X; Zheng J
Acta Derm Venereol; 2020 Jun; 100(13):adv00192. PubMed ID: 32516422
[No Abstract] [Full Text] [Related]
19. Hydroa vacciniforme-like Epstein-Barr virus-associated lymphoproliferative disease: a case report.
Zeng Y; Fu L; Jin H; Sun Q; Wang B
Pediatr Dermatol; 2012; 29(1):96-100. PubMed ID: 21995788
[TBL] [Abstract][Full Text] [Related]
20. Comparative Study of the Clinical Pathology, Immunophenotype, Epstein-Barr Virus Infection Status, and Gene Rearrangements in Adult and Child Patients With Hydroa Vacciniforme-Like Lymphoproliferative Disorder.
Wen PF; Zhang M; Wang TT; Liu HJ; Zhang WY; Liu WP; Wang L
Am J Dermatopathol; 2019 Jan; 41(1):7-15. PubMed ID: 30085959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
